5 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS
8 Apr 24
Coherus is a commercial-stage biopharmaceutical company focused on researching, developing, and commercializing innovative
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative
Coherus Completes Divestiture of Ophthalmology Franchise
CHRS
4 Mar 24
and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline of tumor microenvironment
Coherus Launches UDENYCA ONBODY For Pegfilgrastim-cbqv
CHRS
21 Feb 24
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time –– Unique, automatic, retractable needle mechanism
- Prev
- 1
- Next